2026-06-14T03:45:08Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/168942024-11-29T08:15:07Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Kislaya, Irina author Sentís, Alexis author Starrfelt, Jostein author Nunes, Baltazar author Martínez-Baz, Iván author Nielsen, Katrine Finderup author AlKerwi, Ala'a author Braeye, Toon author Fontán-Vela, Mario author Bacci, Sabrina author Meijerink, Hinta author Castilla, Jesús author Emborg, Hanne-Dorthe author Hansen, Christian Holm author Schmitz, Susanne author Van Evercooren, Izaak author Valenciano, Marta author Nardone, Anthony author Nicolay, Nathalie author Monge Corella, Susana author VEBIS-Lot4 working group author 2023-11 Background: Within the ECDC-VEBIS project, we prospectively monitored vaccine effectiveness (VE) against COVID-19 hospitalisation and COVID-19-related death using electronic health registries (EHR), between October 2021 and November 2022, in community-dwelling residents aged 65-79 and ≥80 years in six European countries. Methods: EHR linkage was used to construct population cohorts in Belgium, Denmark, Luxembourg, Navarre (Spain), Norway and Portugal. Using a common protocol, for each outcome, VE was estimated monthly over 8-week follow-up periods, allowing 1 month-lag for data consolidation. Cox proportional-hazards models were used to estimate adjusted hazard ratios (aHR) and VE = (1 - aHR) × 100%. Site-specific estimates were pooled using random-effects meta-analysis. Results: For ≥80 years, considering unvaccinated as the reference, VE against COVID-19 hospitalisation decreased from 66.9% (95% CI: 60.1; 72.6) to 36.1% (95% CI: -27.3; 67.9) for the primary vaccination and from 95.6% (95% CI: 88.0; 98.4) to 67.7% (95% CI: 45.9; 80.8) for the first booster. Similar trends were observed for 65-79 years. The second booster VE against hospitalisation ranged between 82.0% (95% CI: 75.9; 87.0) and 83.9% (95% CI: 77.7; 88.4) for the ≥80 years and between 39.3% (95% CI: -3.9; 64.5) and 80.6% (95% CI: 67.2; 88.5) for 65-79 years. The first booster VE against COVID-19-related death declined over time for both age groups, while the second booster VE against death remained above 80% for the ≥80 years. Conclusions: Successive vaccine boosters played a relevant role in maintaining protection against COVID-19 hospitalisation and death, in the context of decreasing VE over time. Multicountry data from EHR facilitate robust near-real-time VE monitoring in the EU/EEA and support public health decision-making. Influenza Other Respir Viruses. 2023 Nov;17(11):e13195. 10.1111/irv.13195 1750-2659 Influenza and other respiratory viruses 38019704 http://hdl.handle.net/20.500.12105/16894 COVID-19 COVID-19-related death SARS-CoV-2 Cohort design Hospitalization Vaccine effectiveness Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022